SCHEMBL20522149

SCHEMBL20522149

CCCc1ccc(OC)c(C(=O)O)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.60
PPARA Q07869 1/20 0.60
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
ALDH1A1 P00352 2/20 0.56
POLB P06746 1/20 0.56
MRGPRX4 Q96LA9 1/20 0.55
CFD P00746 1/20 0.51
DRD2 P14416 1/20 0.50
KAT8 Q9H7Z6 2/20 0.49
MCL1 Q07820 1/20 0.49
MAPK1 P28482 1/20 0.48
METAP2 P50579 1/20 0.48
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
ALOX5 P09917 1/20 0.47
GABRA1 P14867 1/20 0.47
GABRB2 P47870 1/20 0.47
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14398158 0.90 PPARA (0.69) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL11731466 0.88 PPARA (0.79) PPARGPPARAKAT8
SCHEMBL3963370 0.87 PPARA (0.78) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL26104257 0.87 MRGPRX4 (0.55) PPARGPPARAALDH1A1MRGPRX4CFD
SCHEMBL31135560 0.87 MRGPRX4 (0.55) PPARGPPARAALDH1A1MRGPRX4CFD
SCHEMBL2950901 0.87 DRD2 (0.50) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL384685 0.86 MRGPRX4 (0.57) PPARGPPARASMN1; SMN2ALDH1A1MRGPRX4
SCHEMBL1415715 0.86 HPGDS (0.50) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL29196268 0.85 DRD2 (0.49) PPARGPPARANPC1RAB9ASMN1; SMN2
SCHEMBL6866159 0.84 CFD (0.70) PPARGPPARAALDH1A1MRGPRX4CFD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630541-B2 Compounds useful as inhibitors of ALCAT 1 PERENNA PHARMACEUTICALS, INC. (US) 2026-05-19 US disclosed
CN-120136858-A Compounds useful as ALCAT1 inhibitors 中美博瑞纳制药有限公司 2025-06-13 CN disclosed
CN-110709394-B Compounds useful as ALCAT1 inhibitors 中美博瑞纳制药有限公司 2025-02-21 CN disclosed
US-20220089582-A1 COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 PERENNA PHARMACEUTICALS, INC. 2022-03-24 US disclosed
US-11208404-B2 Compounds useful as inhibitors of ALCAT 1 PERENNA PHARMACEUTICALS, INC. (US) 2021-12-28 US disclosed
US-20200109136-A1 COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 PERENNA PHARMACEUTICALS, INC. 2020-04-09 US disclosed
EP-3601274-A1 COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 Perenna Pharmaceuticals, Inc. (US) 2020-02-05 EP disclosed
CN-110709394-A Compounds useful as ALCAT1 inhibitors 中美博瑞纳制药有限公司 2020-01-17 CN disclosed
WO-2018178304-A1 COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 PERENNA PHARMACEUTICALS, INC. (US) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089582-A1 COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 ACAT1, ACAT2, SLC33A1 PPARG 374/4885PPARA 361/4885NPC1 168/4885
US-12630541-B2 Compounds useful as inhibitors of ALCAT 1 LCLAT1, LPCAT1, ACAT2 PPARG 1062/4885PPARA 994/4885NPC1 79/4885
US-11208404-B2 Compounds useful as inhibitors of ALCAT 1 ACAT1, ACAT2, SLC33A1 PPARG 374/4885PPARA 361/4885NPC1 168/4885
US-20200109136-A1 COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 ACAT1, ACAT2, SLC33A1 PPARG 374/4885PPARA 361/4885NPC1 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.